These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 27692523)

  • 1. Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection.
    Mejias A; Garcia-Maurino C; Rodriguez-Fernandez R; Peeples ME; Ramilo O
    Vaccine; 2017 Jan; 35(3):496-502. PubMed ID: 27692523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater
    Zhao M; Zheng ZZ; Chen M; Modjarrad K; Zhang W; Zhan LT; Cao JL; Sun YP; McLellan JS; Graham BS; Xia NS
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28539438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
    Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
    Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults.
    Griffin MP; Khan AA; Esser MT; Jensen K; Takas T; Kankam MK; Villafana T; Dubovsky F
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and Characterization of Phage Display-Derived Human Monoclonal Antibodies against RSV F Glycoprotein.
    Chen Z; Zhang L; Tang A; Callahan C; Pristatsky P; Swoyer R; Cejas P; Nahas D; Galli J; Cosmi S; DiStefano D; Hoang VM; Bett A; Casimiro D; Vora KA
    PLoS One; 2016; 11(6):e0156798. PubMed ID: 27258388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanobodies® specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion.
    Schepens B; Ibañez LI; De Baets S; Hultberg A; Bogaert P; De Bleser P; Vervalle F; Verrips T; Melero J; Vandevelde W; Vanlandschoot P; Saelens X
    J Infect Dis; 2011 Dec; 204(11):1692-701. PubMed ID: 21998474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New options in the treatment of respiratory syncytial virus disease.
    Mejias A; Ramilo O
    J Infect; 2015 Jun; 71 Suppl 1():S80-7. PubMed ID: 25922289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant.
    Schneider-Ohrum K; Cayatte C; Bennett AS; Rajani GM; McTamney P; Nacel K; Hostetler L; Cheng L; Ren K; O'Day T; Prince GA; McCarthy MP
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28148790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for preventing respiratory syncytial virus.
    Forbes M
    Am J Health Syst Pharm; 2008 Dec; 65(23 Suppl 8):S13-9. PubMed ID: 19020197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ongoing developments in RSV prophylaxis: a clinician's analysis.
    Rezaee F; Linfield DT; Harford TJ; Piedimonte G
    Curr Opin Virol; 2017 Jun; 24():70-78. PubMed ID: 28500974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Passive and active immunization against respiratory syncytial virus for the young and old.
    Villafana T; Falloon J; Griffin MP; Zhu Q; Esser MT
    Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28525961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
    Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Broadly Reactive Anti-Respiratory Syncytial Virus G Antibodies from Exposed Individuals Effectively Inhibit Infection of Primary Airway Epithelial Cells.
    Cortjens B; Yasuda E; Yu X; Wagner K; Claassen YB; Bakker AQ; van Woensel JBM; Beaumont T
    J Virol; 2017 May; 91(10):. PubMed ID: 28275185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.
    Liu X; Liang B; Ngwuta J; Liu X; Surman S; Lingemann M; Kwong PD; Graham BS; Collins PL; Munir S
    J Virol; 2017 Nov; 91(22):. PubMed ID: 28835504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats.
    Wyde PR; Moore DK; Hepburn T; Silverman CL; Porter TG; Gross M; Taylor G; Demuth SG; Dillon SB
    Pediatr Res; 1995 Oct; 38(4):543-50. PubMed ID: 8559607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Potential of Prefusion RSV F-specific Antibodies.
    Rossey I; McLellan JS; Saelens X; Schepens B
    Trends Microbiol; 2018 Mar; 26(3):209-219. PubMed ID: 29054341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.
    Zhu Q; McLellan JS; Kallewaard NL; Ulbrandt ND; Palaszynski S; Zhang J; Moldt B; Khan A; Svabek C; McAuliffe JM; Wrapp D; Patel NK; Cook KE; Richter BWM; Ryan PC; Yuan AQ; Suzich JA
    Sci Transl Med; 2017 May; 9(388):. PubMed ID: 28469033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventing severe respiratory syncytial virus disease: passive, active immunisation and new antivirals.
    Murray J; Saxena S; Sharland M
    Arch Dis Child; 2014 May; 99(5):469-73. PubMed ID: 24464977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New strategies for control of respiratory syncytial virus infection.
    Nokes JD; Cane PA
    Curr Opin Infect Dis; 2008 Dec; 21(6):639-43. PubMed ID: 18978532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Respiratory syncytial virus (RSV) immune globulin and palivizumab for prevention of RSV infection.
    Robinson RF; Nahata MC
    Am J Health Syst Pharm; 2000 Feb; 57(3):259-64. PubMed ID: 10674778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.